Shilpa Medicare shares rose over 5% after its subsidiary partnered with Orion to co-develop and supply a nivolumab biosimilar for Europe. Orion will market the drug, while the Shilpa Medicare arm handles manufacturing. The deal aims to expand access to affordable cancer therapy.
